NO20021399L - Kazolinderivater og deres anvendelse som farmasöyter - Google Patents

Kazolinderivater og deres anvendelse som farmasöyter

Info

Publication number
NO20021399L
NO20021399L NO20021399A NO20021399A NO20021399L NO 20021399 L NO20021399 L NO 20021399L NO 20021399 A NO20021399 A NO 20021399A NO 20021399 A NO20021399 A NO 20021399A NO 20021399 L NO20021399 L NO 20021399L
Authority
NO
Norway
Prior art keywords
optionally substituted
hydrogen
3alkyl
organic groups
nhc
Prior art date
Application number
NO20021399A
Other languages
English (en)
Other versions
NO20021399D0 (no
Inventor
Andrew Austen Mortlock
Nicholas John Keen
Federic Henri Jung
Andrew George Brewster
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9922154.1A external-priority patent/GB9922154D0/en
Priority claimed from GBGB9922170.7A external-priority patent/GB9922170D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20021399D0 publication Critical patent/NO20021399D0/no
Publication of NO20021399L publication Critical patent/NO20021399L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20021399A 1999-09-21 2002-03-20 Kazolinderivater og deres anvendelse som farmasöyter NO20021399L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9922154.1A GB9922154D0 (en) 1999-09-21 1999-09-21 Chemical compounds
GBGB9922170.7A GB9922170D0 (en) 1999-09-21 1999-09-21 Chemical compounds
PCT/GB2000/003580 WO2001021596A1 (en) 1999-09-21 2000-09-18 Quinazoline derivatives and their use as pharmaceuticals

Publications (2)

Publication Number Publication Date
NO20021399D0 NO20021399D0 (no) 2002-03-20
NO20021399L true NO20021399L (no) 2002-04-30

Family

ID=26315940

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20021399A NO20021399L (no) 1999-09-21 2002-03-20 Kazolinderivater og deres anvendelse som farmasöyter

Country Status (24)

Country Link
US (1) US7709479B1 (no)
EP (1) EP1218354B1 (no)
JP (1) JP4870304B2 (no)
KR (1) KR20020032612A (no)
CN (1) CN1391562A (no)
AT (1) ATE449083T1 (no)
AU (1) AU7301000A (no)
BG (1) BG106492A (no)
BR (1) BR0014116A (no)
CA (1) CA2384291A1 (no)
CO (1) CO5200785A1 (no)
CZ (1) CZ20021009A3 (no)
DE (1) DE60043349D1 (no)
EE (1) EE200200119A (no)
ES (1) ES2334879T3 (no)
HK (1) HK1046686A1 (no)
HU (1) HUP0300059A3 (no)
IL (1) IL148576A0 (no)
IS (1) IS6305A (no)
NO (1) NO20021399L (no)
PL (1) PL354323A1 (no)
RU (1) RU2002110461A (no)
SK (1) SK3822002A3 (no)
WO (1) WO2001021596A1 (no)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1208085B1 (en) 1999-08-04 2007-12-05 Icagen, Inc. Benzanilides as potassium channel openers
US6495550B2 (en) * 1999-08-04 2002-12-17 Icagen, Inc. Pyridine-substituted benzanilides as potassium ion channel openers
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
AU2001278609B2 (en) 2000-08-21 2005-04-14 Astrazeneca Ab Quinazoline derivatives
DE60144284D1 (de) 2000-11-01 2011-05-05 Millennium Pharm Inc Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
US7132427B2 (en) * 2001-06-21 2006-11-07 Ariad Pharmaceuticals, Inc. Quinazolines and uses thereof
JP4383870B2 (ja) * 2001-10-17 2009-12-16 協和発酵キリン株式会社 線維芽細胞増殖因子受容体自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物
WO2003035602A1 (en) * 2001-10-25 2003-05-01 Sankyo Company, Limited Lipid modulators
ATE446093T1 (de) * 2001-12-24 2009-11-15 Astrazeneca Ab Substituierte chinazolin-derivate als aurora- kinase inhibitoren
RS63204A (sr) 2002-01-17 2006-10-27 Neurogen Corporation Supstituisani analozi hinazolin-4-ilamina kao modulatori kapsaicina
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
EP1521747B1 (en) * 2002-07-15 2018-09-05 Symphony Evolution, Inc. Receptor-type kinase modulators and methods of use
JP2006512306A (ja) * 2002-08-29 2006-04-13 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション アリール及びヘテロアリールプロペンアミド、それらの誘導体並びにそれらの治療用途
AU2003296984A1 (en) 2002-12-13 2004-07-09 Neurogen Corporation 2-substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators
KR20050085749A (ko) * 2002-12-18 2005-08-29 화이자 프로덕츠 인크. 비정상적 세포 성장의 치료를 위한 4-아닐리노 퀴나졸린유도체
WO2004058752A1 (en) 2002-12-24 2004-07-15 Astrazeneca Ab Quinazoline compounds
UA83814C2 (ru) 2002-12-24 2008-08-26 Астразенека Аб Производные фосфонооксихиназолина и их фармацевтическое применение
RU2005135337A (ru) * 2003-04-16 2006-06-10 Астразенека Аб (Se) Производные хиназолина для лечения злокачественного новообразования
DE602004015108D1 (de) * 2003-06-02 2008-08-28 Astrazeneca Ab (3-((chinazolin-4-yl)amino)-1h-pyrazol-1-yl)acetamid derivate und verwandte verbindungen als aurora kinase inhibitoren zur behandlung von proliferativen erkrankungen wie krebs
AU2003304266A1 (en) * 2003-07-03 2005-01-21 Cambridge University Technical Services Ltd Use of aurora kinase inhibitors for reducing the resistance of cancer cells
CA2531327A1 (en) 2003-07-03 2005-01-13 Myriad Genetics, Inc. Compounds and therapeutical use thereof
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
US7691870B2 (en) * 2003-07-11 2010-04-06 Merck Patent Gmbh Benzimidazole carboxamides as raf kinase inhibitors
US7329664B2 (en) 2003-07-16 2008-02-12 Neurogen Corporation Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
GB0317665D0 (en) 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
WO2005026150A1 (en) 2003-09-16 2005-03-24 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
GB0322409D0 (en) 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
EP2210607B1 (en) * 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
WO2005037825A2 (en) 2003-10-14 2005-04-28 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein kinase inhibitors
US20090099165A1 (en) 2003-10-14 2009-04-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
WO2005048953A2 (en) 2003-11-13 2005-06-02 Ambit Biosciences Corporation Amide derivatives as kinase modulators
GB0326459D0 (en) * 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
US7572914B2 (en) 2003-12-19 2009-08-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
ATE413389T1 (de) 2004-02-03 2008-11-15 Astrazeneca Ab Chinazolinderivate
US7166738B2 (en) 2004-04-23 2007-01-23 Roche Palo Alto Llc Non-nucleoside reverse transcriptase inhibitors
US7625949B2 (en) 2004-04-23 2009-12-01 Roche Palo Alto Llc Methods for treating retroviral infections
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US7432373B2 (en) 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
WO2006023931A2 (en) 2004-08-18 2006-03-02 Takeda San Diego, Inc. Kinase inhibitors
JPWO2006025490A1 (ja) * 2004-09-01 2008-05-08 田辺三菱製薬株式会社 分子シャペロン機能調節剤
TW200624431A (en) 2004-09-24 2006-07-16 Hoffmann La Roche Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
US7285569B2 (en) 2004-09-24 2007-10-23 Hoff Hoffmann-La Roche Inc. Tricycles, their manufacture and use as pharmaceutical agents
MX2007004403A (es) 2004-10-12 2007-04-27 Astrazeneca Ab Derivados de quinazolina.
EP1812439B2 (en) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
CA2603204A1 (en) 2005-04-14 2006-10-19 F. Hoffmann-La Roche Ag Aminopyrazole derivatives, their manufacture and use as pharmaceutical agents
CN101189239A (zh) * 2005-04-28 2008-05-28 休普基因公司 蛋白激酶抑制剂
GB0509227D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
US7732613B2 (en) 2005-09-14 2010-06-08 Bristol-Myers Squibb Company Met kinase inhibitors
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
EP1940781A1 (en) 2005-10-19 2008-07-09 F.Hoffmann-La Roche Ag Phenyl-acetamide nnrt inhibitors
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
EP2016065B1 (en) 2005-12-28 2012-09-19 Vertex Pharmaceuticals Incorporated 1-(benzo[d][1,3]dioxol-5-yl)-n-(phenyl)cyclopropane-carboxamide derivatives and related compounds as modulators of atp-binding cassette transporters for the treatment of cystic fibrosis
CN101003514A (zh) 2006-01-20 2007-07-25 上海艾力斯医药科技有限公司 喹唑啉衍生物、其制备方法及用途
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
JPWO2008001886A1 (ja) 2006-06-30 2009-11-26 協和発酵キリン株式会社 オーロラ（Ａｕｒｏｒａ）阻害剤
JP2010505962A (ja) 2006-10-09 2010-02-25 武田薬品工業株式会社 キナーゼ阻害剤
EP2078008A2 (en) * 2006-10-12 2009-07-15 SuperGen, Inc. Quinoline derivatives for modulating dna methylation
KR101390076B1 (ko) 2006-11-08 2014-04-29 브리스톨-마이어스 스큅 컴퍼니 피리디논 화합물
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
JP5377332B2 (ja) 2007-02-06 2013-12-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 二環式へテロ環、それらの化合物を含む薬剤、その使用及びその製法
JP2010524909A (ja) * 2007-04-16 2010-07-22 シプラ・リミテッド ゲフィチニブの製造方法
EP2220054A2 (en) 2007-10-29 2010-08-25 Natco Pharma Limited Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents
NZ586418A (en) * 2007-12-19 2012-09-28 Cancer Rec Tech Ltd Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
EA017736B1 (ru) 2008-01-23 2013-02-28 Бристол-Маерс Сквибб Компани Соединения 4-пиридинона и их применение для лечения рака
WO2009098061A1 (de) 2008-02-07 2009-08-13 Boehringer Ingelheim International Gmbh Spirocyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
CA2727103A1 (en) * 2008-07-03 2010-01-07 Merck Patent Gmbh Naphthyridinones as aurora kinase inhibitors
EP2149565A1 (de) * 2008-07-24 2010-02-03 Bayer Schering Pharma AG Sulfonsubstituierte Chinazolinderivate als Immunmodulatoren zur Behandlung von enzündlichen und allergischen Erkrankungen
EP2313397B1 (de) 2008-08-08 2016-04-20 Boehringer Ingelheim International GmbH Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
TW201920110A (zh) * 2009-01-16 2019-06-01 美商艾克塞里克斯公司 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
KR101699991B1 (ko) * 2009-02-11 2017-01-26 메르크 파텐트 게엠베하 신규의 아미노 아자헤테로시클릭 카르복사미드
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
EP2473487B1 (en) 2009-09-03 2016-10-26 Bristol-Myers Squibb Company Quinazolines as potassium ion channel inhibitors
EP2937345B1 (en) * 2009-12-29 2018-03-21 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
KR101217526B1 (ko) * 2010-06-11 2013-01-02 한미사이언스 주식회사 아마이드 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물
EP2423208A1 (en) * 2010-08-28 2012-02-29 Lead Discovery Center GmbH Pharmaceutically active compounds as Axl inhibitors
JP6026441B2 (ja) 2011-03-04 2016-11-16 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ キナーゼ阻害剤としてのアミノキノリン
US8658655B2 (en) * 2011-03-24 2014-02-25 Fox Chase Cancer Center Inhibition of activated cdc42-associated kinase 1
KR101317809B1 (ko) 2011-06-07 2013-10-16 한미약품 주식회사 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
AR092530A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
AR092529A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
KR20140096571A (ko) 2013-01-28 2014-08-06 한미약품 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법
CN105143208B (zh) 2013-02-21 2017-09-26 葛兰素史密斯克莱知识产权发展有限公司 作为激酶抑制剂的喹唑啉
WO2014148136A1 (ja) * 2013-03-19 2014-09-25 岐阜市 抗アレルギー活性化合物及びその用途
HUE034490T2 (en) 2013-09-16 2018-02-28 Astrazeneca Ab Therapeutic polymer nanoparticles and methods for their preparation and use
AU2015315174B2 (en) * 2014-09-10 2019-12-12 Epizyme, Inc. Smyd inhibitors
CN107427521B (zh) 2015-03-27 2021-08-03 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
WO2016168704A1 (en) * 2015-04-16 2016-10-20 Icahn School Of Medicine At Mount Sinai Ksr antagonists
WO2017011323A1 (en) 2015-07-10 2017-01-19 University Of Maryland, Baltimore Small molecule inhibitors of the mcl-1 oncoprotein and uses thereof
US20190112317A1 (en) 2015-10-05 2019-04-18 The Trustees Of Columbia University In The City Of New York Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
CN105384699B (zh) 2015-10-23 2016-10-12 中国人民解放军南京军区南京总医院 一种新型喹唑啉衍生物lu1501及其制备方法和应用
CN105503836B (zh) * 2015-12-03 2018-04-24 中国人民解放军南京军区南京总医院 一种新型喹唑啉衍生物lu1502及其制备方法和应用
CN105399689B (zh) * 2015-12-03 2017-03-01 中国人民解放军南京军区南京总医院 一种新型喹唑啉衍生物lu1503及其制备方法和应用
CN105541807B (zh) * 2015-12-03 2018-04-24 中国人民解放军南京军区南京总医院 一种新型喹唑啉衍生物lu1506及其制备方法和应用
CN105503835B (zh) * 2015-12-03 2018-04-24 中国人民解放军南京军区南京总医院 一种新型喹唑啉衍生物lu1510及其制备方法和应用
CN105481835B (zh) * 2015-12-03 2018-09-04 中国人民解放军南京军区南京总医院 一种喹唑啉衍生物lu1508及其制备方法和应用
CN105503747B (zh) * 2015-12-03 2017-12-19 中国人民解放军南京军区南京总医院 一种喹唑啉衍生物lu1507及其制备方法和应用
CN105418517B (zh) * 2015-12-03 2017-03-22 中国人民解放军南京军区南京总医院 一种新型喹唑啉衍生物lu1509及其制备方法和应用
CN105461642B (zh) * 2015-12-03 2017-03-22 中国人民解放军南京军区南京总医院 一种新型喹唑啉衍生物lu1505及其制备方法和应用
CN105884699B (zh) * 2016-05-11 2019-05-07 中国药科大学 4-取代苯胺喹唑啉类衍生物及其制备方法和用途
AU2018259078B2 (en) * 2017-04-27 2021-10-07 Astrazeneca Ab C5-anilinoquinazoline compounds and their use in treating cancer
US11053223B2 (en) * 2017-04-27 2021-07-06 Astrazeneca Ab Phenoxyquinazoline compounds and their use in treating cancer
WO2019028463A1 (en) 2017-08-04 2019-02-07 Bioventures, Llc LINEAR LIPOPEPTIDE PAENIPEPTINS AND METHODS OF USE
CN110372666B (zh) * 2018-04-13 2022-11-08 华东理工大学 喹唑啉类化合物作为egfr三突变抑制剂及其应用
WO2020049208A1 (es) 2018-09-09 2020-03-12 Fundacio Privada Institut De Recerca De La Sida - Caixa Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
CN111303024B (zh) * 2018-12-12 2023-03-28 安徽中科拓苒药物科学研究有限公司 一种喹啉结构的pan-KIT激酶抑制剂及其用途
CN113164477A (zh) 2018-12-14 2021-07-23 达纳-法伯癌症研究所股份有限公司 C-jun-n-末端激酶的吡唑并吡啶抑制剂及其用途
CN109776432B (zh) * 2019-03-21 2020-07-24 广州六顺生物科技股份有限公司 一种多靶点激酶抑制剂、药物组合物及多靶点激酶抑制剂的制备方法和应用
CN112778217B (zh) * 2019-11-08 2024-01-26 沈阳化工研究院有限公司 一种喹唑啉类化合物及其应用
CN114948964B (zh) * 2021-02-25 2023-10-03 石药集团中奇制药技术（石家庄）有限公司 多靶点蛋白激酶抑制剂的用途
CN113004211A (zh) * 2021-03-29 2021-06-22 鲁东大学 喹唑啉-4-硒醚衍生物及制备方法和生物活性
WO2024259060A1 (en) * 2023-06-16 2024-12-19 Kinnate Biopharma Inc. Inhibitors of met kinase
CN118772070B (zh) * 2024-06-12 2025-12-16 天津济坤医药科技有限公司 一种喹唑啉衍生物及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL78381B2 (no) * 1972-08-09 1975-06-30
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
DE4208254A1 (de) * 1992-03-14 1993-09-16 Hoechst Ag Substituierte pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel und fungizid
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (no) * 1994-11-12 1997-12-01 Zeneca Ltd
DE69622183D1 (de) * 1995-11-07 2002-08-08 Kirin Brewery Chinolinderivate und chinazolinderivate welche die autophosphorylierung des von blutplättchen abstammenden wachstumsfaktorrezeptors inhibiren und sie enthaltende pharmazeutische zusammensetzungen
JP3944241B2 (ja) * 1995-12-18 2007-07-11 スージェン・インコーポレーテッド Ａｕｒ―１および／またはａｕｒ―２関連疾患の診断および処置
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CA2242425C (en) * 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
NZ331191A (en) * 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
JPH107657A (ja) * 1996-06-19 1998-01-13 Sankyo Co Ltd スルホンアミド化合物
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US6251912B1 (en) * 1997-08-01 2001-06-26 American Cyanamid Company Substituted quinazoline derivatives
GB9800575D0 (en) * 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
RS49779B (sr) * 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
CN1158266C (zh) * 1998-10-01 2004-07-21 阿斯特拉曾尼卡有限公司 化合物

Also Published As

Publication number Publication date
SK3822002A3 (en) 2002-10-08
DE60043349D1 (de) 2009-12-31
US7709479B1 (en) 2010-05-04
WO2001021596A1 (en) 2001-03-29
EE200200119A (et) 2003-04-15
HUP0300059A2 (hu) 2003-07-28
ES2334879T3 (es) 2010-03-17
EP1218354A1 (en) 2002-07-03
CA2384291A1 (en) 2001-03-29
BR0014116A (pt) 2002-05-21
NO20021399D0 (no) 2002-03-20
AU7301000A (en) 2001-04-24
EP1218354B1 (en) 2009-11-18
IL148576A0 (en) 2002-09-12
HUP0300059A3 (en) 2003-08-28
IS6305A (is) 2002-03-18
ATE449083T1 (de) 2009-12-15
RU2002110461A (ru) 2004-03-10
PL354323A1 (en) 2004-01-12
JP4870304B2 (ja) 2012-02-08
JP2003509499A (ja) 2003-03-11
CN1391562A (zh) 2003-01-15
CZ20021009A3 (cs) 2002-06-12
BG106492A (bg) 2003-01-31
KR20020032612A (ko) 2002-05-03
CO5200785A1 (es) 2002-09-27
HK1046686A1 (zh) 2003-01-24

Similar Documents

Publication Publication Date Title
NO20021399D0 (no) Kazolinderivater og deres anvendelse som farmasöytika
MX9709951A (es) Derivados de benzamida y su uso como antagonistas de vasopresina.
DK0862567T3 (da) 5-azabicyclo[3.1.0]hexylalkyl-2-piperidoner og-glutarimider som neurokininreceptorantagonister
DK0876366T3 (da) Angiogenese-inhiberende pyridazinaminer
ES2322602T3 (es) Compuestos heterotetraciclicos condensados y su uso como inhibidor de polimerasa del vhc.
DK1265606T3 (da) Celleadhæsionsinhibitorer
SE0202463D0 (sv) Novel compounds
HUP0301607A2 (hu) Szelektív neurokinin antagonista hatású nitrogéntartalmú heterociklusos vegyületek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
AR015312A1 (es) Compuestos inhibidores no peptidilicos de la union a las celulas dependientes de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunesy respiratorias, composicion farmaceutica y uso de los compuestos en la preparacion de medicamentos
DK1412354T3 (da) Derivater af triazolylimidazopyridin og af triazolylpurinerne, der er egnede som ligander for adenosin A2a?-receptoren og deres anvendelse som medikamenter
TR200201205T2 (tr) N-ikame edilmiş karbamoiloksialkil-azolyum türevleri.
NO20025641D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
DE69507293D1 (de) Benzamid-derivate als vasopressin-antagonisten
NO20025640D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
CL2004001050A1 (es) Compuesto derivado de 3'-[4-oxo-3-{[(ciclopropil o 2,2,2-trifluoroetil)amino]carbonil}-1,8-naftiridin-1(4h)-il]-3-sustituido-1-1'-bifenil-4-il; composicion farmaceutica; y uso en el tratamiento o prevencion de asma, bronquitis cronica, enfermedad pul
NO20052074L (no) Substituerte benzoksazinoner og anvendelser derav.
EP1400513A4 (en) UNSYMMETRIC CYCLIC DIAMOND COMPOUND
TR200001010T2 (tr) Ürokinaz önleyicileri olan izokinolinler.
BG104717A (en) Water soluble azoles as broad-spectrum antifungals
TW200505446A (en) Inhibitor of cox
DK0790248T3 (da) 3-Aza-piperidon-(tetrahydropyrimidin-2-on)- og 3-oxa-piperidon-(1,3-oxazin-2-on)-derivater, deres fremstilling og deres anvendelse som tachykinin/neurokinin-antagonister
AR044175A1 (es) Compuestos de cefemo
CY1105459T1 (el) Συνθεσεις που πepιεχουν εποθιλονες και η χρηση τους για τη θepαπεια του καρκινοειδους συνδρομου
AR045950A1 (es) Compuestos derivados de piperazina, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos.
MXPA05009607A (es) Derivados de n-fenil-[(4-piridil)-azinil]-amina como agentes protectores de plantas.